Nonalcoholic fatty liver disease and cardiovascular disease

World Journal of Gastroenterology

Volumn , Issue 26, 2014, Pages 8407-8415

  Liu, Hong ^a   Lu, Hong Yun ^a  

^a SUN YAT SEN UNIVERSITY   (China)

Author keywords

Cardiovascular disease; Metabolic syndrome; Nonalcoholic fatty liver disease; Risk assessment

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; 8 HYDROXYDEOXYGUANOSINE; ADIPONECTIN; ALANINE AMINOTRANSFERASE; ANTIOXIDANT; APOLIPOPROTEIN A1; APOLIPOPROTEIN B; BILE ACID; C REACTIVE PROTEIN; GASTRIC INHIBITORY POLYPEPTIDE; GLUCAGON LIKE PEPTIDE 1; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INTERLEUKIN 6; INTERLEUKIN 8; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; PIOGLITAZONE; PLASMINOGEN ACTIVATOR INHIBITOR 1; SIBUTRAMINE; STEROL REGULATORY ELEMENT BINDING PROTEIN 1C; TETRAHYDROLIPSTATIN; TISSUE PLASMINOGEN ACTIVATOR; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR INHIBITOR; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL; ANTILIPEMIC AGENT; ANTIOBESITY AGENT; CYTOPROTECTIVE AGENT; INCRETIN; INSULIN SENSITIZING AGENT; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

ARTICLE; ATHEROSCLEROSIS; BARIATRIC SURGERY; BEHAVIOR MODIFICATION; BODY FAT DISTRIBUTION; CARDIOVASCULAR DISEASE; CHRONIC KIDNEY DISEASE; DISEASE ASSOCIATION; DYSLIPIDEMIA; ENDOTHELIAL DYSFUNCTION; FIBRINOLYSIS; HEART ATRIUM FIBRILLATION; HUMAN; HYPERCOAGULABILITY; INFLAMMATION; INSULIN RESISTANCE; INTRAABDOMINAL FAT; META ANALYSIS (TOPIC); METABOLIC SYNDROME X; MULTICENTER STUDY (TOPIC); NON INSULIN DEPENDENT DIABETES MELLITUS; NONALCOHOLIC FATTY LIVER; NONHUMAN; OBESITY; OXIDATIVE STRESS; PHASE 2 CLINICAL TRIAL (TOPIC); PHLEBOTOMY; POSTPRANDIAL STATE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK ASSESSMENT; SLEEP DISORDERED BREATHING; CARDIOVASCULAR RISK; DIABETES MELLITUS; ECTOPIC ADIPOSE TISSUE DISTRIBUTION; ECTOPIC TISSUE; ISCHEMIC HEART DISEASE; LIVER BIOPSY; PREVALENCE; ANIMAL; CARDIOVASCULAR DISEASES; COMORBIDITY; DISEASE COURSE; METABOLISM; NON-ALCOHOLIC FATTY LIVER DISEASE; PATHOPHYSIOLOGY; PROGNOSIS; RISK FACTOR;

ANIMALS; CARDIOVASCULAR DISEASES; COMORBIDITY; DISEASE PROGRESSION; HUMANS; NON-ALCOHOLIC FATTY LIVER DISEASE; PREVALENCE; PROGNOSIS; RISK ASSESSMENT; RISK FACTORS;

EID: 84904390832     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v20.i26.8407     Document Type: Article

References (77)

1. Hashizume H, Sato K, Yamazaki Y, Horiguchi N, Kakizaki S, Mori M. A prospective study of long-term outcomes in female patients with nonalcoholic steatohepatitis using age-and body mass index-matched cohorts. Acta Med Okayama 2013; 67: 45-53 [PMID: 23439508]
2. Blackett PR, Sanghera DK. Genetic determinants of cardiometabolic risk: a proposed model for phenotype association and interaction. J Clin Lipidol 2013; 7: 65-81 [PMID: 23351585 DOI: 10.1016/j.jacl.2012.04.079]
3. Nestel PJ, Mensink RP. Perspective: nonalcoholic fatty liver disease and cardiovascular risk. Curr Opin Lipidol 2013; 24: 1-3 [PMID: 23298957 DOI: 10.1097/MOL.0b013e32835c0834]
4. Williams KH, Shackel NA, Gorrell MD, McLennan SV, Twigg SM. Diabetes and nonalcoholic Fatty liver disease: a pathogenic duo. Endocr Rev 2013; 34: 84-129 [PMID: 23238855 DOI: 10.1210/er.2012-1009]
5. Kucukazman M, Ata N, Yavuz B, Dal K, Sen O, Deveci OS, Agladioglu K, Yeniova AO, Nazligul Y, Ertugrul DT. Evaluation of early atherosclerosis markers in patients with nonalcoholic fatty liver disease. Eur J Gastroenterol Hepatol 2013; 25: 147-151 [PMID: 23085576]
6. Gökc¸e S, Atbinici Z, Aycan Z, Cinar HG, Zorlu P. The relationship between pediatric nonalcoholic fatty liver disease and cardiovascular risk factors and increased risk of atherosclerosis in obese children. Pediatr Cardiol 2013; 34: 308-315 [PMID: 22875138 DOI: 10.1007/s00246-012-0447-9]
7. Leite NC, Villela-Nogueira CA, Pannain VL, Bottino AC, Rezende GF, Cardoso CR, Salles GF. Histopathological stages of nonalcoholic fatty liver disease in type 2 diabetes: prevalences and correlated factors. Liver Int 2011; 31: 700-706 [PMID: 21457442 DOI: 10.1111/j.1478-3231.2011]
8. Lu H, Liu H, Hu F, Zou L, Luo S, Sun L. Independent Association between Nonalcoholic Fatty Liver Disease and Cardiovascular Disease: A Systematic Review and Meta-Analysis. Int J Endocrinol 2013; 2013: 124958 [PMID: 23690766 DOI: 10.1155/2013/124958]
9. Targher G, Mantovani A, Pichiri I, Rigolon R, Dauriz M, Zoppini G, Morani G, Vassanelli C, Bonora E. Non-alcoholic fatty liver disease is associated with an increased prevalence of atrial fibrillation in hospitalized patients with type 2 diabetes. Clin Sci (Lond) 2013; 125: 301-309 [PMID: 23596966 DOI: 10.1042/CS20130036]
10. DeFilippis AP, Blaha MJ, Martin SS, Reed RM, Jones SR, Nasir K, Blumenthal RS, Budoff MJ. Nonalcoholic fatty liver disease and serum lipoproteins: the Multi-Ethnic Study of Atherosclerosis. Atherosclerosis 2013; 227: 429-436 [PMID: 23419204 DOI: 10.]
11. Feitosa MF, Reiner AP, Wojczynski MK, Graff M, North KE, Carr JJ, Borecki IB. Sex-influenced association of nonalcoholic fatty liver disease with coronary heart disease. Atherosclerosis 2013; 227: 420-424 [PMID: 23390892 DOI: 10.1016/j.atherosclerosis.2013.01.013]
12. Akin L, Kurtoglu S, Yikilmaz A, Kendirci M, Elmali F, Mazicioglu M. Fatty liver is a good indicator of subclinical atherosclerosis risk in obese children and adolescents regardless of liver enzyme elevation. Acta Paediatr 2013; 102: e107-e113 [PMID: 23190373 DOI: 10.1111/apa.12099]
13. Huang Y, Bi Y, Xu M, Ma Z, Xu Y, Wang T, Li M, Liu Y, Lu J, Chen Y, Huang F, Xu B, Zhang J, Wang W, Li X, Ning G. Nonalcoholic fatty liver disease is associated with atherosclerosis in middle-aged and elderly Chinese. Arterioscler Thromb Vasc Biol 2012; 32: 2321-2326 [PMID: 22814750 DOI: 10.1161/ATVBAHA.112.252957]
14. Catena C, Bernardi S, Sabato N, Grillo A, Ermani M, Sechi LA, Fabris B, Carretta R, Fallo F. Ambulatory arterial stiffness indices and non-alcoholic fatty liver disease in essential hypertension. Nutr Metab Cardiovasc Dis 2013; 23: 389-393 [PMID: 22796347 DOI: 10.1016/2012.05.007]
15. Colak Y, Senates E, Yesil A, Yilmaz Y, Ozturk O, Doganay L, Coskunpinar E, Kahraman OT, Mesci B, Ulasoglu C, Tuncer I. Assessment of endothelial function in patients with nonalcoholic fatty liver disease. Endocrine 2013; 43: 100-107 [PMID: 22661277]
16. de Carvalho SC, Muniz MT, Siqueira MD, Siqueira ER, Gomes AV, Silva KA, Bezerra LC, D'Almeida V, de Oliveira CP, Pereira LM. Plasmatic higher levels of homocysteine in non-alcoholic fatty liver disease (NAFLD). Nutr J 2013; 12: 37 [PMID: 23547829]
17. Thakur ML, Sharma S, Kumar A, Bhatt SP, Luthra K, Guleria R, Pandey RM, Vikram NK. Nonalcoholic fatty liver disease is associated with subclinical atherosclerosis independent of obesity and metabolic syndrome in Asian Indians. Atherosclerosis 2012; 223: 507-511 [PMID: 22748277 DOI: 10.1016/j.atherosclerosis.2012.06.005]
18. Arslan U, Kocaoʇlu I, Balci M, Duyuler S, Korkmaz A. The association between impaired collateral circulation and nonalcoholic fatty liver in patients with severe coronary artery disease. J Cardiol 2012; 60: 210-214 [PMID: 22738690 DOI: 10.1016/j.jjcc.2012.05.003]
19. Beaton MD . Current treatment options for nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. Can J Gastroenterol 2012; 26: 353-357 [PMID: 22720278]
20. Cakir E, Ozbek M, Colak N, Cakal E, Delibaşi T. Is NAFLD an independent risk factor for increased IMT in T2DM? Minerva Endocrinol 2012; 37: 187-193 [PMID: 22691891]
21. Bhatia LS, Curzen NP, Byrne CD. Nonalcoholic fatty liver disease and vascular risk. Curr Opin Cardiol 2012; 27: 420-428 [PMID: 22596186 DOI: 10.1097/HCO.0b013e328354829c]
22. Severova MM, Saginova EA, Galliamov MG, Ermakov NV, Rodina AV, Fomin VV, Mukhin NA. [Clinicopathogenetic characteristics of cardiorenal syndrome in non-alcoholic fatty liver disease]. Ter Arkh 2012; 84: 15-20 [PMID: 22997912]
23. Heuer M, Kaiser GM, Kahraman A, Banysch M, Saner FH, Mathé Z, Gerken G, Paul A, Canbay A, Treckmann JW. Liver transplantation in nonalcoholic steatohepatitis is associated with high mortality and post-transplant complications: a single-center experience. Digestion 2012; 86: 107-113 [PMID: 22846254 DOI: 10.1159/000339344]
24. Wang CC, Tseng TC, Hsieh TC, Hsu CS, Wang PC, Lin HH, Kao JH. Severity of fatty liver on ultrasound correlates with metabolic and cardiovascular risk. Kaohsiung J Med Sci 2012; 28: 151-160 [PMID: 22385608 DOI: 10.1016/j.kjms.2011.10.005]
25. Brown TM. Nonalcoholic fatty liver disease and cardiovascular disease risk. Clin Gastroenterol Hepatol 2012; 10: 568-569 [PMID: 22387255 DOI: 10.1016/j.cgh.2012.02.023]
26. Coracina A, Gaiani S, Cosma A, Pellizzari P, Pizzi C, de Kreutzenberg S, Cecchet D, Sacerdoti D, Tessari P. No association between the degree of liver steatosis and early signs of vasculopathy in T2DM. Nutr Metab Cardiovasc Dis 2012; 22: e11-e12 [PMID: 22397876 DOI: 10.1016/2011.11.008]
27. Bhatia LS, Curzen NP, Calder PC, Byrne CD. Non-alcoholic fatty liver disease: a new and important cardiovascular risk factor? Eur Heart J 2012; 33: 1190-1200 [PMID: 22408036 DOI: 10.1093/eurheartj/ehr453]
28. Chatrath H, Vuppalanchi R, Chalasani N. Dyslipidemia in patients with nonalcoholic fatty liver disease. Semin Liver Dis 2012; 32: 22-29 [PMID: 22418885 DOI: 10.1055/s-0032-1306423]
29. Treeprasertsuk S, Leverage S, Adams LA, Lindor KD, St Sauver J, Angulo P. The Framingham risk score and heart disease in nonalcoholic fatty liver disease. Liver Int 2012; 32: 945-950 [PMID: 22299674 DOI: 10.1111/j.1478-3231.2011.02753.x]
30. Kim D, Choi SY, Park EH, Lee W, Kang JH, Kim W, Kim YJ, Yoon JH, Jeong SH, Lee DH, Lee HS, Larson J, Therneau TM, Kim WR. Nonalcoholic fatty liver disease is associated with coronary artery calcification. Hepatology 2012; 56: 605-613 [PMID: 22271511 DOI: 10.1002/hep.25593]
31. Stepanova M, Younossi ZM. Independent association between nonalcoholic fatty liver disease and cardiovascular disease in the US population. Clin Gastroenterol Hepatol 2012; 10: 646-650 [PMID: 22245962 DOI: 10.1016/j.cgh.2011.12.039]
32. Li G, Hu H, Shi W, Li Y, Liu L, Chen Y, Hu X, Wang J, Gao J, Yin D. Elevated hematocrit in nonalcoholic fatty liver disease: a potential cause for the increased risk of cardiovascular disease? Clin Hemorheol Microcirc 2012; 51: 59-68 [PMID: 22240370 DOI: 10.3233/CH-2011-1509]
33. Bonapace S, Perseghin G, Molon G, Canali G, Bertolini L, Zoppini G, Barbieri E, Targher G. Nonalcoholic fatty liver disease is associated with left ventricular diastolic dysfunction in patients with type 2 diabetes. Diabetes Care 2012; 35: 389-395 [PMID: 22210573 DOI: 10.2337/dc11-1820]
34. Ahmed MH, Abu EO, Byrne CD. Non-Alcoholic Fatty Liver Disease (NAFLD): new challenge for general practitioners and important burden for health authorities? Prim Care Diabetes 2010; 4: 129-137 [PMID: 20299294 DOI: 10.1016/j.pcd.2010.02.004]
35. Hacihamdioʇlu B, Okutan V, Yozgat Y, Yildirim D, Kocaoʇlu M, Lenk MK, Ozcan O. Abdominal obesity is an independent risk factor for increased carotid intima- media thickness in obese children. Turk J Pediatr 2011; 53: 48-54 [PMID: 21534339]
36. Dogru T, Genc H, Tapan S, Ercin CN, Ors F, Aslan F, Kara M, Sertoglu E, Bagci S, Kurt I, Sonmez A. Elevated asymmetric dimethylarginine in plasma: an early marker for endothelial dysfunction in non-alcoholic fatty liver disease? Diabetes Res Clin Pract 2012; 96: 47-52 [PMID: 22189171 DOI: 10.1016/j.diabres.2011.11.022]
37. Alkhouri N, Kistangari G, Campbell C, Lopez R, Zein NN, Feldstein AE. Mean platelet volume as a marker of increased cardiovascular risk in patients with nonalcoholic steatohepatitis. Hepatology 2012; 55: 331 [PMID: 21969091 DOI: 10.1002/hep.24721]
38. Motta AB. Report of the international symposium: polycystic ovary syndrome: first Latin-American consensus. Int J Clin Pract 2010; 64: 544-557 [PMID: 20456209 DOI: 10.1111/j.1742-1241.2009.02259.x]
39. Gawrieh S, Baye TM, Carless M, Wallace J, Komorowski R, Kleiner DE, Andris D, Makladi B, Cole R, Charlton M, Curran J, Dyer TD, Charlesworth J, Wilke R, Blangero J, Kissebah AH, Olivier M. Hepatic gene networks in morbidly obese patients with nonalcoholic fatty liver disease. Obes Surg 2010; 20: 1698-1709 [PMID: 20473581 DOI: 10.1007/s11695-010-0171-6]
40. Hessheimer AJ, Forner A, Varela M, Bruix J. Metabolic risk factors are a major comorbidity in patients with cirrhosis independent of the presence of hepatocellular carcinoma. Eur J Gastroenterol Hepatol 2010; 22: 1239-1244 [PMID: 20505515 DOI: 10.1097/MEG.0b013e32833aa19b]
41. Lee YJ, Shim JY, Moon BS, Shin YH, Jung DH, Lee JH, Lee HR. The relationship between arterial stiffness and nonalcoholic fatty liver disease. Dig Dis Sci 2012; 57: 196-203 [PMID: 21750929 DOI: 10.1007/s10620-011-1819-3]
42. Ahmed MH, Barakat S, Almobarak AO. Nonalcoholic fatty liver disease and cardiovascular disease: has the time come for cardiologists to be hepatologists? J Obes 2012; 2012: 483135 [PMID: 23320150 DOI: 10.1155/2012/483135]
43. Hurjui DM, Nit¸ə O, Graur LI, Mihalache L, Popescu DS, Hut¸anaşu IC, Ungureanu D, Graur M. Non-alcoholic fatty liver disease is associated with cardiovascular risk factors of metabolic syndrome. Rev Med Chir Soc Med Nat Iasi 2012; 116: 692-699 [PMID: 23272512]
44. Cameron I, Alam MA, Wang J, Brown L. Endurance exercise in a rat model of metabolic syndrome. Can J Physiol Pharmacol 2012; 90: 1490-1497 [PMID: 23078220 DOI: 10.1139/y2012-097]
45. Santos RD, Agewall S. Non-alcoholic fatty liver disease and cardiovascular disease. Atherosclerosis 2012; 224: 324-325 [PMID: 22840429 DOI: 10.1016/j.atherosclerosis.2012.07.018]
46. Hurjui DM, Nit¸ə O, Graur LI, Mihalache L, Popescu DS, Graur M. The central role of the non alcoholic fatty liver disease in metabolic syndrome. Rev Med Chir Soc Med Nat Iasi 2012; 116: 425-431 [PMID: 23077931]
47. Swarbrick MM, Stanhope KL, Elliott SS, Graham JL, Krauss RM, Christiansen MP, Griffen SC, Keim NL, Havel PJ. Consumption of fructose-sweetened beverages for 10 weeks increases postprandial triacylglycerol and apolipo-protein-B concentrations in overweight and obese women. Br J Nutr 2008; 100: 947-952 [PMID: 18384705 DOI: 10.1017/Sooo7114508968252]
48. Senateş E, Colak Y, Yeşil A, Coşkunpinar E, Sahin O, Kahraman OT, Erkalma şenate? B, Tuncer I. Circulating resistin is elevated in patients with non-alcoholic fatty liver disease and is associated with steatosis, portal inflammation, insulin resistance and nonalcoholic steatohepatitis scores. Minerva Med 2012; 103: 369-376 [PMID: 23042372]
49. Vlachopoulos C, Manesis E, Baou K, Papatheodoridis G, Koskinas J, Tiniakos D, Aznaouridis K, Archimandritis A, Stefanadis C. Increased arterial stiffness and impaired endothelial function in nonalcoholic Fatty liver disease: a pilot study. Am J Hypertens 2010; 23: 1183-1189 [PMID: 20634799 DOI: 10.1038/ajh.2010.144]
50. Brandt ML, Harmon CM, Helmrath MA, Inge TH, McKay SV, Michalsky MP. Morbid obesity in pediatric diabetes mellitus: surgical options and outcomes. Nat Rev Endocrinol 2010; 6: 637-645 [PMID: 20842181 DOI: 10.1038/nrendo.2010.167]
51. Fan JG, Zhou Q, Wo QH. [Effect of body weight mass and its change on the incidence of nonalcoholic fatty liver disease]. Zhonghua Gan Zang Bing Zazhi 2010; 18: 676-679 [PMID: 20943079 DOI: 10.3760/cma.j.issn.1007-3418.2010.09.008]
52. Rivera R, Vanaclocha F. [Nonalcoholic fatty liver disease and psoriasis]. Actas Dermosifiliogr 2010; 101: 657-658 [PMID: 20965008]
53. Ashburn DD, Reed MJ. Gastrointestinal system and obesity. Crit Care Clin 2010; 26: 625-627 [PMID: 20970047 DOI: 10.1016/j.ccc.2010.06.006]
54. RoѤtberg GE, Sharkhun OO, Ushakova TI. [Non-alcoholic fatty liver disease as an atherosclerosis risk factor]. Eksp Klin Gastroenterol 2010; (7): 20-24 [PMID: 21033079]
55. Kwon YM, Oh SW, Hwang SS, Lee C, Kwon H, Chung GE. Association of nonalcoholic fatty liver disease with components of metabolic syndrome according to body mass index in Korean adults. Am J Gastroenterol 2012; 107: 1852-1858 [PMID: 23032980 DOI: 10.1038/ajg.2012.314]
56. Bəloşeanu CL, Streba CT, Vere CC, Comənescu V, Rogoveanu I. Association between liver histology, carotid ultrasonography and retinal vascular changes in patients with nonalcoholic fatty liver disease (NAFLD). Rom J Morphol Embryol 2012; 53: 609-614 [PMID: 22990555]
57. Kubes P, Mehal WZ. Sterile inflammation in the liver. Gastroenterology 2012; 143: 1158-1172 [PMID: 22982943 DOI: 10.1053/j.gastro.2012.09.008]
58. Li X, Xia M, Ma H, Hofman A, Hu Y, Yan H, He W, Lin H, Jeekel J, Zhao N, Gao J, Gao X. Liver fat content is associated with increased carotid atherosclerosis in a Chinese middle-aged and elderly population: the Shanghai Changfeng study. Atherosclerosis 2012; 224: 480-485 [PMID: 22884916 DOI: 10.1016/j.atherosclerosis.2012.07.002]
59. Yang YY, Huang YT, Lee TY, Chan CC, Yeh YC, Lee KC, Lin HC. Rho-kinase-dependent pathway mediates the hepatoprotective effects of sorafenib against ischemia/reperfusion liver injury in rats with nonalcoholic steatohepatitis. Liver Transpl 2012; 18: 1371-1383 [PMID: 22847887 DOI: 10.1002/lt.23520]
60. Saleh DA, Ismail MA, Ibrahim AM. Non alcoholic fatty liver disease, insulin resistance, dyslipidemia and atherogenic ratios in epileptic children and adolescents on long term antiepileptic drug therapy. Pak J Biol Sci 2012; 15: 68-77 [PMID: 22545359]
61. Ampuero J, Romero-Gómez M. [Influence of non-alcoholic fatty liver disease on cardiovascular disease]. Gastroenterol Hepatol 2012; 35: 585-593 [PMID: 22541252 DOI: 10.1016/j.2012.02.005]
62. Mantovani A, Zoppini G, Targher G, Golia G, Bonora E. Non-alcoholic fatty liver disease is independently associated with left ventricular hypertrophy in hypertensive Type 2 diabetic individuals. J Endocrinol Invest 2012; 35: 215-218 [PMID: 22490991]
63. Koskinen J, Magnussen CG, Kähönen M, Loo BM, Marniemi J, Jula A, Saarikoski LA, Huupponen R, Viikari JS, Raitakari OT, Juonala M. Association of liver enzymes with metabolic syndrome and carotid atherosclerosis in young adults. The Cardiovascular Risk in Young Finns Study. Ann Med 2012; 44: 187-195 [PMID: 21254896 DOI: 10.3109/07853890.2010.532152]
64. Samson SL, Bajaj M. Potential of incretin-based therapies for non-alcoholic fatty liver disease. J Diabetes Complications 2013; 27: 401-406 [PMID: 23352496]
65. Leuschner UF, Lindenthal B, Herrmann G, Arnold JC, Rössle M, Cordes HJ, Zeuzem S, Hein J, Berg T. High-dose ursodeoxycholic acid therapy for nonalcoholic steatohepatitis: a double-blind, randomized, placebo-controlled trial. Hepatology 2010; 52: 472-479 [PMID: 20683947 DOI: 10.1002/hep.23727]
66. Ratziu V, de Ledinghen V, Oberti F, Mathurin P, Wartelle-Bladou C, Renou C, Sogni P, Maynard M, Larrey D, Serfaty L, Bonnefont-Rousselot D, Bastard JP, Rivière M, Spénard J. A randomized controlled trial of high-dose ursodesoxycholic acid for nonalcoholic steatohepatitis. J Hepatol 2011; 54: 1011-1019 [PMID: 21145828 DOI: 10.1016/j.jhep2010.08.030]
67. Sanyal AJ, Chalasani N, Kowdley KV, McCullough A, Diehl AM, Bass NM, Neuschwander-Tetri BA, Lavine JE, Tonascia J, Unalp A, Van Natta M, Clark J, Brunt EM, Kleiner DE, Hoofnagle JH, Robuck PR. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med 2010; 362: 1675-1685 [PMID: 20427778 DOI: 10.1056/NEJMoa0907929]
68. Lavine JE, Schwimmer JB, Van Natta ML, Molleston JP, Murray KF, Rosenthal P, Abrams SH, Scheimann AO, Sanyal AJ, Chalasani N, Tonascia J, Ünalp A, Clark JM, Brunt EM, Kleiner DE, Hoofnagle JH, Robuck PR. Effect of vitamin E or metformin for treatment of nonalcoholic fatty liver disease in children and adolescents: the TONIC randomized controlled trial. JAMA 2011; 305: 1659-1668 [PMID: 21521847 DOI: 10.1001/jama.2011.520]
69. Adams LA, Zein CO, Angulo P, Lindor KD. A pilot trial of pentoxifylline in nonalcoholic steatohepatitis. Am J Gastroenterol 2004; 99: 2365-2368 [PMID: 15571584] (Pubitemid 40039367)
70. Satapathy SK, Sakhuja P, Malhotra V, Sharma BC, Sarin SK. Beneficial effects of pentoxifylline on hepatic steatosis, fibrosis and necroinflammation in patients with non-alcoholic steatohepatitis. J Gastroenterol Hepatol 2007; 22: 634-638 [PMID: 17444848] (Pubitemid 46608380)
71. Nseir W, Mograbi J, Ghali M. Lipid-lowering agents in nonalcoholic fatty liver disease and steatohepatitis: human studies. Dig Dis Sci 2012; 57: 1773-1781 [PMID: 22419057 DOI: 10.1007/s10620-012-2118-3]
72. Dixon JB. Surgical management of obesity in patients with morbid obesity and nonalcoholic fatty liver disease. Clin Liver Dis 2014; 18: 129-146 [PMID: 24274869]
73. Beaton MD, Chakrabarti S, Levstik M, Speechley M, Marotta P, Adams P. Phase II clinical trial of phlebotomy for nonalcoholic fatty liver disease. Aliment Pharmacol Ther 2013; 37: 720-729 [PMID: 23441892 DOI: 10.1111/apt.12255]
74. Harrison AG. Fragmentation reactions of methionine-containing protonated octapeptides and fragment ions therefrom: an energy-resolved study. J Am Soc Mass Spectrom 2013; 24: 1555-1564 [PMID: 23943431 DOI: 10.1007/s.13361-013-0706-x]
75. Harrison SA, Fecht W, Brunt EM, Neuschwander-Tetri BA. Orlistat for overweight subjects with nonalcoholic steatohepatitis: A randomized, prospective trial. Hepatology 2009; 49: 80-86 [PMID: 19053049 DOI: 10.1002/hep.22575]
76. Tziomalos K, Krassas GE, Tzotzas T. The use of sibutramine in the management of obesity and related disorders: an update. Vasc Health Risk Manag 2009; 5: 441-452 [PMID: 19475780]
77. Filippatos TD, Derdemezis CS, Gazi IF, Nakou ES, Mikhailidis DP, Elisaf MS. Orlistat-associated adverse effects and drug interactions: a critical review. Drug Saf 2008; 31: 53-65 [PMID: 18095746]